Pham, Thu-ThiNimptsch, KatharinaAleksandrova, KrasimiraJenab, MazdaReichmann, RobinWu, KanaTjønneland, AnneKyrø, CecilieSchulze, Matthias BKaaks, RudolfKatzke, VerenaPalli, DomenicoPasanisi, FabrizioRicceri, FulvioTumino, RosarioKrogh, VittorioRoodhart, JeanineCastilla, JesúsSanchez-Perez, Maria-JoseColorado-Yohar, Sandra MilenaHarbs, JustinRutegård, MartinPapier, KerenAglago, Elom KDimou, NikiMayen-Chacon, Ana-LuciaWeiderpass, ElisabetePischon, Tobias2023-05-032023-05-032022-12-01Pham TT, Nimptsch K, Aleksandrova K, Jenab M, Reichmann R, Wu K, et al. Pre-Diagnostic Circulating Resistin Concentrations Are Not Associated with Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study. Cancers (Basel). 2022 Nov 9;14(22):5499.2072-6694http://hdl.handle.net/10668/20927Resistin is a polypeptide implicated in inflammatory processes, and as such could be linked to colorectal carcinogenesis. In case-control studies, higher resistin levels have been found in colorectal cancer (CRC) patients compared to healthy individuals. However, evidence for the association between pre-diagnostic resistin and CRC risk is scarce. We investigated pre-diagnostic resistin concentrations and CRC risk within the European Prospective Investigation into Cancer and Nutrition using a nested case-control study among 1293 incident CRC-diagnosed cases and 1293 incidence density-matched controls. Conditional logistic regression models controlled for matching factors (age, sex, study center, fasting status, and women-related factors in women) and potential confounders (education, dietary and lifestyle factors, body mass index (BMI), BMI-adjusted waist circumference residuals) were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for CRC. Higher circulating resistin concentrations were not associated with CRC (RR per doubling resistin, 1.11; 95% CI 0.94-1.30; p = 0.22). There were also no associations with CRC subgroups defined by tumor subsite or sex. However, resistin was marginally associated with a higher CRC risk among participants followed-up maximally two years, but not among those followed-up after more than two years. We observed no substantial correlation between baseline circulating resistin concentrations and adiposity measures (BMI, waist circumference), adipokines (adiponectin, leptin), or metabolic and inflammatory biomarkers (C-reactive protein, C-peptide, high-density lipoprotein cholesterol, reactive oxygen metabolites) among controls. In this large-scale prospective cohort, there was little evidence of an association between baseline circulating resistin concentrations and CRC risk in European men and women.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/colorectal cancerinflammationpre-diagnostic resistinprospectiveriskCholesterolLipoproteins, HDLBiomarkersColorectal NeoplasmsCarcinogenesisFastingProtein CIncidenceResistinAdiposityC-Reactive ProteinAdiponectinAdipokinesC-PeptideLeptinresearch article36428592open accessAdiponectinaAdipoquinasAdiposidadCarcinogénesisAyunoColesterolLeptinaLipoproteínas HDLNeoplasias colorrectalesProteína CProteína C-Reactiva10.3390/cancers14225499PMC9688251https://www.mdpi.com/2072-6694/14/22/5499/pdf?version=1669261737https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688251/pdf